QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
Conditions:  Hepatocellular Carcinoma Non-resectable;  Hepatocellular Carcinoma Recurrent Interventions:  Biological: ALT-803;  Biological: ETBX-011;  Biological: GI-4000;  Biological: haNK for infusion;  Biological: avelumab;  Drug: Capecitabine;  Drug: Cyclophosphamide;  Drug: 5-Fluorouracil;  Drug: Leucovorin;  Drug: nab-Paclitaxel;  Drug: Sorafenib;  Procedure:  SBRT;  Biological: Aldoxorubicin hydrochloride;  Biological: ETBX-051;  Biological: ETBX-061;  Biological: GI-6207;  Biological: GI-6301;  Drug: Cetuximab Sponsor:  NantKwest, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Erbitux | Hepatocellular Carcinoma | Liver Cancer | Research | Vaccines | Xeloda